Srdan Verstovsek, MD, PhD

Articles

Dr. Verstovsek on the Potential Role of Rusfertide in Polycythemia Vera

September 26th 2022

Srdan Verstovsek, MD, PhD, discusses the potential for rusfertide in polycythemia vera.

Dr. Verstovsek on Pemigatinib in FGFR1-Rearranged Myeloid Neoplasms

September 14th 2022

Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.

Dr. Verstovsek on the Future of ALK2 Inhibitors in Myelofibrosis

May 4th 2022

Srdan Verstovsek, MD, PhD, discusses the future of ALK2 inhibitors in myelofibrosis.

Dr. Verstovsek on Addressing Anemia in Patients with Myelofibrosis

May 3rd 2022

Srdan Verstovsek, MD, PhD, discusses addressing anemia in patients with myelofibrosis.

Dr. Verstovsek on the Mechanism of Action of Momelotinib in Myelofibrosis

April 25th 2022

Srdan Verstovsek, MD, PhD, discusses the mechanisms of action of momelotinib in myelofibrosis.

Dr. Verstovsek on the Efficacy of Momelotinib in Myelofibrosis

April 1st 2022

Srdan Verstovsek, MD, PhD, discusses the efficacy of momelotinib in myelofibrosis.

Dr. Verstovsek on the Tolerability of Momelotinib in Myelofibrosis

January 28th 2022

Srdan Verstovsek, MD, PhD, discusses the tolerability of momelotinib in myelofibrosis.

Dr. Verstovsek on the Goal of the IMPactMF Trial With Imetelstat in Myelofibrosis

January 11th 2022

Srdan Verstovsek, MD, PhD, discusses the key objective of the phase 3 IMpactMF trial examining imetelstat in patients with myelofibrosis.

Updates in AML and MPNs From ASH 2021: From Drs Srdan Verstovsek and Naval Daver

December 13th 2021

OncLive® speaks with Dr. Srdan Verstovsek on the pivotal data in myeloproliferative neoplasms, and Dr. Naval Daver on some intriguing findings in acute myeloid leukemia.

Dr. Verstovsek on the Benefit of JAK Inhibitor Combos in Myelofibrosis

October 13th 2021

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Dr. Verstovsek Discusses Research Efforts in Myelofibrosis-Related Anemia

September 10th 2021

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

Dr. Verstovsek on Efficacy of Pelabresib Plus Ruxolitinib in Myelofibrosis

July 19th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of the combination of pelabresib plus ruxolitinib in the treatment of patients with myelofibrosis.

Dr. Verstovsek on the Efficacy of Pacritinib in Myelofibrosis

June 17th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy demonstrated with pacritinib in the treatment of patients with myelofibrosis.

Dr. Verstovsek on the Rationale for Utilizing Ruxolitinib/Navitoclax in Relapsed/Refractory Myelofibrosis

May 21st 2021

Srdan Verstovsek, MD, PhD, discusses the rationale for utilizing ruxolitinib and navitoclax in patients with relapsed/refractory myelofibrosis.

Dr. Verstovsek on Future Research Efforts in MPNs

May 18th 2021

Srdan Verstovsek, MD, PhD, discusses future research efforts for patients with myeloproliferative neoplasms.

Dr. Verstovsek on Real-World Survival Data With Ruxolitinib in Myelofibrosis

May 10th 2021

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

Dr. Verstovsek on the Efficacy of Ruxolitinib Plus CPI-0610 in Myelofibrosis

May 3rd 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Dr. Verstovsek on the Potential Utility of Luspatercept in Myelofibrosis

April 15th 2021

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

Dr. Verstovsek on the Role of Prognostication in Myelofibrosis

April 7th 2021

Srdan Verstovsek, MD, PhD, discusses the role of prognostication in myelofibrosis.

Dr. Verstovsek on the Use of Luspatercept to Treat Anemia Associated With Myelofibrosis

February 16th 2021

Srdan Verstovsek, MD, PhD, discusses the use of luspatercept to treat anemia associated with myelofibrosis.